Top

International Journal of Clinical Oncology

Published in:

01-04-2018 | Original Article

Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin

Authors: Toshiyuki Kitai, Kenya Yamanaka

Published in: International Journal of Clinical Oncology | Issue 2/2018

Abstract

Background

The purpose of this study was to clarify the role of repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) in the management of recurrent peritoneal carcinomatosis of appendiceal origin.

Methods

Data were retrieved on 42 patients who underwent CRS + HIPEC; 29 repeat surgical procedures were performed in 13 patients.

Results

Complete cytoreduction was achieved in 12 of 13 patients by the second CRS. Repeat recurrence was detected in 11 patients, eight of whom underwent a third CRS. The peritoneal cancer index decreased from initial CRS to repeat CRS but was still higher than 18 in nine patients at the second CRS. Preoperative chemotherapy was given to three patients with early recurrence. Grade 3–5 morbidity and 90-day mortality were not significantly different between initial and repeat CRS. Five-year survival rates after first and second CRS were 75.5 and 67.7%, respectively. Complete cytoreduction at second CRS was a significant prognostic factor. Among patients with recurrence after the second CRS, patients who underwent a third CRS showed a better prognosis than those who did not.

Conclusions

Repeat CRS is oncologically beneficial, and the morbidity rate was as high as that of initial CRS. Complete cytoreduction was the key to successful long-term results. Although further recurrence was common, aggressive resection was useful, even in cases of diffuse recurrence.

Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69–76CrossRefPubMed

Yan TD, Black D, Savady R et al (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14:484–492CrossRefPubMed

Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456CrossRefPubMed

Mogal H, Chouliaras K, Levine EA et al (2016) Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol 7:129–142PubMedPubMedCentral

Esquivel J, Sugarbaker PH (2001) Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg 234:198–205CrossRefPubMedPubMedCentral

Bijelic L, Yan TD, Sugarbaker PH (2008) Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol 98:295–299CrossRefPubMed

Lord AC, Shihab O, Chandrakumaran K et al (2015) Recurrence and outcome after complete tumor removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumors. Eur J Surg Oncol 41:396–399CrossRefPubMed

Smeenk RM, Verwaal VJ, Antonini N et al (2007) Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol 14:493–499CrossRefPubMed

Delhorme JB, Honoré C, Benhaim L et al (2017) Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. Eur J Surg Oncol 43:159–167CrossRefPubMed

10.

Sardi A, Jimenez WA, Nieroda C et al (2013) Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Eur J Surg Oncol 39:1207–1213CrossRefPubMed

11.

Saxena A, Yan TD, Morris DL (2010) Critical assessment of preoperative and operative risk factors for complications after iterative peritonectomy procedures. Eur J Surg Oncol 36:309–314CrossRefPubMed

12.

Mohamed F, Chang D (2003) Sugarbaker PH (1995) Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination. J Surg Oncol 83:5–13CrossRefPubMed

13.

Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42CrossRefPubMedPubMedCentral

14.

Moran B, Baratti D, Yan TD et al (2008) Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasm with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 98:277–282CrossRefPubMed

15.

Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85–91CrossRefPubMed

16.

Chua TC, Quinn LE, Zhao J et al (2013) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastasis. J Surg Oncol 108:81–88CrossRefPubMed

17.

Chua TC, Liauw W, Morris DL (2012) Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome. Int J Colorectal Dis 27:381–389CrossRefPubMed

18.

Konstantinidis IT, Levine EA, Chouliaras K et al (2017) Interval between cytoreductions as a marker of tumor biology in selecting patients for repeatcytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. https://doi.org/10.1002/jso.24703 PubMed

19.

Pietrantonio F, Maggi C, Fanetti G et al (2014) FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 19:845–850CrossRefPubMedPubMedCentral

20.

Bijelic L, Kumar AS, Stuart OA et al (2012) Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. Gastroenterol Res Pract 2012:163284. https://doi.org/10.1155/2012/163284 PubMedPubMedCentral

Title: Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin
Authors: Toshiyuki Kitai
Kenya Yamanaka
Publication date: 01-04-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1217-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib

MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression

Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group

Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma

Monitoring the estimated glomerular filtration rate (eGFR) in patients with small-cell lung cancer during chemotherapy: equations based on serum creatinine or cystatin C?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer